Table 1 Patient characteristics of the paired sample cohort. NOS: not otherwise specified. The data is shown as median and interquartile range or numbers with percentage of the paired cohort (n = 19 patients).
Paired 19 patients with PM from CRC | |
|---|---|
Age | 46y (39y – 60y) |
Gender (f/m) | 10 (52.6%)/9 (47.4%) |
Median DFS | 14 months |
Median OS | 39 months |
T-stage of the primary tumor | |
T3 | 5 (26.3%) |
T4 | 14 (73.7%) |
N-stage of the primary tumor | |
N0 | 3 (15.8%) |
N1 | 8 (42.1%) |
N2 | 8 (42.1%) |
G-stage/histological grading | |
G1 | 6 (31.5%) |
G2 | 9 (47.4%) |
G3 | 4 (21.1%) |
Histological subtype | |
Adenocarcinoma NOS | 16 (84.2%) |
Signet cell differentiation | 3 (15.8%) |
PCI (median, IQR) | 8 (6–16) |
PM occurence | 12 (63.2%) synchronous |
7 (36.8%) metachronous | |
RAS mutations | |
Wild-type | 10 (52.6%) |
KRAS mutation | 7 (36.8%) |
NRAS mutation | 2 (10.5%) |
No systemic chemotherapy prior CRS/HIPEC | 5 (26.3%) |
Neoadjuvant chemotherapy | 14 (73.7%) |
Douplet drug combination (FOLFOX/FOLFIRI) | 11 (57.9%) |
Triplet drug combination (FOLFOXIRI) | 3 (15.8%) |
Adjuvant/additive chemotherapy | |
First line | 18 (94.7%) |
Single drug (Capecitabine) | 4 (21.1%) |
Douplet drug combination (FOLFOX/FOLFIRI) | 5 (26.3%) |
+ VEGF antagonist | 5 (26.3%) |
+ EGFR antagonist | 2 (10.5%) |
Triplet drug combination + VEGF antagonist (FOLFOXIRI) | 2 (10.5%) |
No of cycles (median, IQR) | 6 (3–9) |
